Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 13c

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($1.31), $0.13 worse than the analyst estimate of ($1.18).

“2019 was a year of outstanding execution for Deciphera,” said Steve Hoerter, President and Chief Executive Officer. “In 2020, our top priority is preparing for the potential approval and launch of ripretinib now that the NDA has been accepted by the FDA for Priority Review. Patients with GIST are in need of a new treatment option, and we believe ripretinib has the potential to transform the treatment of this disease.”

Mr. Hoerter continued, “Our broad development program for ripretinib is on track, and we look forward to the completion of enrollment in INTRIGUE, our pivotal Phase 3 study of ripretinib in second-line GIST, in the second half of this year. Beyond ripretinib, we remain focused on the balance of our wholly-owned, clinical-stage pipeline, with updated clinical data for both DCC-3014 and rebastinib, as well as an IND submission for DCC-3116, expected later this year.”

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• Provident Financial Services (PFS) Tops Q1 EPS by 3c
• Independent Bank (INDB) Misses Q1 EPS by 3c